Guilherme Loureiro Werneck

Dr. Guilherme Loureiro Werneck

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Cadernos de Saude Publica
Verified
Journal Article
Open access
PDF file
GWGuilherme Loureiro Werneck
Guilherme Loureiro Werneck
MCMarilia Sá Carvalho
Marilia Sá Carvalho
O insuficiente conhecimento científico sobre o novo coronavírus, sua alta velocidade de disseminação e capacidade de provocar mortes em populações vulneráveis, geram incertezas sobre quais seriam as melhores estratégias a serem utilizadas para o enfrentamento da epidemia em diferentes partes do mundo. No Brasil, os desafios são ainda maiores, pois pouco se sabe sobre as características de transmissão da COVID-19 num contexto de grande desigualdade social, com populações vivendo em condições precárias de habitação e saneamento, sem acesso sistemático à água e em situação de aglomeração.

9 February 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
TCThiago Cerqueira-Silva Cerqueira-Silva
Thiago Cerqueira-Silva Cerqueira-Silva
SKSrinivasa Vittal Katikireddi
Srinivasa Vittal Katikireddi
VOVinicius de Araujo Oliveira
Vinicius de Araujo Oliveira
RFRenzo Flores-Ortiz
Renzo Flores-Ortiz
JJJuracy Bertoldo Júnior
Juracy Bertoldo Júnior
VBViviane Sampaio Boaventura
Viviane Sampaio Boaventura
There is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19) vaccines and vaccine effectiveness (VE) of booster doses. Using linked national Brazilian databases, we undertook a test-negative design study involving almost 14 million people (~16 million tests) to estimate VE of CoronaVac over time and VE of BNT162b2 booster vaccination against RT–PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 outcomes (hospitalization or death). Compared with unvaccinated individuals, CoronaVac VE at 14–30 d after the second dose was 55.0% (95% confidence interval (CI): 54.3–55.7) against confirmed infection and 82.1% (95% CI: 81.4–82.8) against severe outcomes. VE decreased to 34.7% (95% CI: 33.1–36.2) against infection and 72.5% (95% CI: 70.9–74.0) against severe outcomes over 180 d after the second dose. A BNT162b2 booster, 6 months after the second dose of CoronaVac, improved VE against infection to 92.7% (95% CI: 91.0−94.0) and VE against severe outcomes to 97.3% (95% CI: 96.1−98.1) 14–30 d after the booster. Compared with younger age groups, individuals 80 years of age or older had lower protection after the second dose but similar protection after the booster. Our findings support a BNT162b2 booster vaccine dose after two doses of CoronaVac, particularly for the elderly.

1 October 2014 in Revista de Saúde Pública
Verified
Journal Article
Open access
PDF file
GWGuilherme Loureiro Werneck
Guilherme Loureiro Werneck
The control of zoonotic visceral leishmaniasis is a challenge, particularly in Brazil, where the disease has been gradually spreading across the country over the past 30 years. Strategies employed for decreasing the transmission risk are based on the control of vector populations and reservoirs; since humans are considered unnecessary for the maintenance of transmission. Among the adopted strategies in Brazil, the sacrifice of infected dogs is commonly performed and has been the most controversial measure. In the present study, we provide the rationale for the implementation of different control strategies targeted at reservoir populations and highlight the limitations and concerns associated with each of these strategies.

6 July 2020 in Revista de Saúde Pública
Verified
Journal Article
Open access
PDF file
LALuiz Amorim
Luiz Amorim
CSCelia Landmann Szwarcwald
Celia Landmann Szwarcwald
SMSheila de Oliveira Garcia Mateos
Sheila de Oliveira Garcia Mateos
ALAntonio Ponce de Leon
Antonio Ponce de Leon
RMRoberto Medronho
Roberto Medronho
GWGuilherme Loureiro Werneck
Guilherme Loureiro Werneck
OBJECTIVE: To estimate the seroprevalence of antibodies to SARS-CoV-2 among blood donors in the state of Rio de Janeiro, Brazil. METHODS: Data were collected on 2,857 blood donors from April 14 to 27, 2020. This study reports crude prevalence of antibodies to SARS-CoV-2, population weighted prevalence for the state, and prevalence adjusted for test sensitivity and specificity. Logistic regression models were used to establish the correlates of SARS-CoV-2 prevalence. For the analysis, we considered collection period and site, sociodemographic characteristics, and place of residence. RESULTS: The proportion of positive tests for SARS-Cov-2, without any adjustment, was 4.0% (95%CI 3.3–4.7%), and the weighted prevalence was 3.8% (95%CI 3.1–4.5%). We found lower estimates after adjusting for test sensitivity and specificity: 3.6% (95%CI 2.7–4.4%) for the non-weighted prevalence, and 3.3% (95%CI 2.6–4.1%) for the weighted prevalence. Collection period was the variable most significantly associated with crude prevalence: the later the period, the higher the prevalence. Regarding sociodemographic characteristics, the younger the blood donor, the higher the prevalence, and the lower the education level, the higher the odds of testing positive for SARS-Cov-2 antibody. We found similar results for weighted prevalence. CONCLUSIONS: Our findings comply with some basic premises: the increasing trend over time, as the epidemic curve in the state is still on the rise; and the higher prevalence among both the youngest, for moving around more than older age groups, and the less educated, for encountering more difficulties in following social distancing recommendations. Despite the study limitations, we may infer that Rio de Janeiro is far from reaching the required levels of herd immunity against SARS-CoV-2.

1 January 2020 in Revista Brasileira de Epidemiologia
Verified
Journal Article
Open access
PDF file
MBMauricio L Barreto
Mauricio L Barreto
ABAluisio Jardim Dornellas de Barros
Aluisio Jardim Dornellas de Barros
MCMarília Sá Carvalho
Marília Sá Carvalho
CCClaudia Torres Codeço
Claudia Torres Codeço
PHPedro Rodrigues Curi Hallal
Pedro Rodrigues Curi Hallal
GWGuilherme Loureiro Werneck
Guilherme Loureiro Werneck
A pandemia por Covid-19 representa um dos maiores desafios sanitários em escala mundial desse século. Na primeira semana do mês de abril, poucos meses depois do início da epidemia na China, em dezembro de 2019, já foram reportados mais de 1,5 milhão de casos e 85 mil mortes no mundo2, e espera-se que um número ainda maior de casos e óbitos venha a ocorrer nos próximos meses. No Brasil, até o dia oito de abril de 2020, foram registrados 15.927 casos confirmados e 800 mortes pelo Covid-193.

10 May 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
AMAlejandro Macias
Alejandro Macias
GWGuilherme Loureiro Werneck
Guilherme Loureiro Werneck
RCRaúl Castro
Raúl Castro
CMCesar Mascareñas
Cesar Mascareñas
LCLaurent Coudeville
Laurent Coudeville
MTMyew-Ling Toh
Myew-Ling Toh
Dengue patients with comorbidities may be at higher risk of death. In this cross-sectional study, healthcare databases from Mexico (2008–2014), Brazil (2008–2015), and Colombia (2009–2017) were used to identify hospitalized dengue cases and their comorbidities. Case fatality rates (CFRs), relative risk, and odds ratios (OR) for in-hospital mortality were determined. Overall, 678,836 hospitalized dengue cases were identified: 68,194 from Mexico, 532,821 from Brazil, and 77,821 from Colombia. Of these, 35%, 5%, and 18% were severe dengue, respectively. Severe dengue and age ≥ 46 years were associated with increased risk of in-hospital mortality. Comorbidities were identified in 8%, 1%, and 4% of cases in Mexico, Brazil, and Colombia, respectively. Comorbidities increased hospitalized dengue CFRs 3- to 17-fold; CFRs were higher with comorbidities regardless of dengue severity or age. The odds of in-hospital mortality were significantly higher in those with pulmonary disorders (11.6 [95% CI 7.4–18.2], 12.7 [95% CI 9.3–17.5], and 8.0 [95% CI 4.9–13.1] in Mexico, Brazil, and Colombia, respectively), ischemic heart disease (23.0 [95% CI 6.6–79.6], 5.9 [95% CI 1.4–24.6], and 7.0 [95% CI 1.9–25.5]), and renal disease/failure (8.3 [95% CI 4.8–14.2], 8.0 [95% CI 4.5–14.4], and 9.3 [95% CI 3.1–28.0]) across the three countries; the odds of in-hospital mortality from dengue with comorbidities was at least equivalent or higher than severe dengue alone (4.5 [95% CI 3.4–6.1], 9.6 [95% CI 8.6–10.6], and 9.0 [95% CI 6.8–12.0). In conclusion, the risk of death because of dengue increases with comorbidities independently of age and/or disease severity.